Skip to content

NIH researcher reinstated after clash with Trump-era policies on science funding

A whistleblower's fight for scientific integrity ends in victory—but not without exposing deep rifts between research and politics. Her return restores critical kidney disease funding.

The image shows the National Institutes of Health (NIH) logo, which consists of a blue circle with...
The image shows the National Institutes of Health (NIH) logo, which consists of a blue circle with a white outline and a white star in the center, surrounded by the words "NIH" in white lettering. The logo is set against a blue background, and the text is written in a bold, modern font.

NIH researcher reinstated after clash with Trump-era policies on science funding

Jenna Norton, a researcher at the National Institutes of Health (NIH), was reinstated to her role in June 2026 after an eight-month paid leave. Her suspension followed the organisation of a public letter criticising the Trump administration’s handling of medical research. The case also involved a whistleblower complaint and legal challenges over grant cancellations tied to an executive order. Norton, who specialises in reducing disparities in kidney disease treatment, became a central figure in opposition to Trump-era policies. In 2025, she helped draft The Bethesda Declaration, a letter signed by nearly 500 NIH employees. The document condemned the administration’s impact on scientific funding and research integrity.

Her troubles began in November 2025, when a 43-day government shutdown led to her being sent home with pay. Shortly after, she filed a whistleblower complaint. NIH Director Dr. Jay Bhattacharya accused her of potentially violating the Antideficiency Act and agency communications rules—claims her lawyer, Debra S. Katz, firmly rejected. Norton’s legal team argued that her involvement in the declaration was protected under the First Amendment. Meanwhile, an executive order by President Trump had already halted many of the grants she managed. Some of these were later reinstated following lawsuits. Before her return, Norton admitted concerns that her position might have changed significantly during her absence. By mid-2026, the NIH reversed its decision, allowing her to resume work at the National Institute for Diabetes and Digestive and Kidney Diseases.

Norton’s reinstatement closes a contentious chapter for the NIH and its employees. The case highlights ongoing tensions between federal research agencies and political directives. Her return also restores key grants that had been paused, ensuring continuity in her work on kidney disease disparities.

Read also:

Latest